AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03678584 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medium Supplemented with Chaetoglobosin A
Description: A medium with in-house supplementation of Chaetoglobosin A to decrease oocyte degeneration after ICSI and improve the survival rate
Study NCT05008068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin with PRF at site of osteotome
Study NCT05008068 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Simvastatin with PRF at site of osteotome
Study NCT00615797 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin
Description: intravenous immunoglobulin 2g/kg total given over 2 days
Study NCT00615797 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: standard interventions penicillin VK and haloperidol
Description: Penicillin V K 500mg 12hrly po or 250mg 6 hrly for 10 days IM penicillin to be given at discharge, 1.2 million units if over 30 KG and 600,000 units if weight less than 30 KG haloperidol 0,025mg/kg/day orally in divided doses gradually increasing to a maximum of 0,05mg/kg/day
Study NCT04938362 — intervention group
Intervention type: OTHER
Intervention: FDG-PET
Description: \[18F\]Deoxyglucose-positron emission tomography at 0-10 years after brain abscess
Study NCT04938362 — intervention group
Intervention type: OTHER
Intervention: EEG
Description: Electroencephalography (EEG) at 0-10 years after brain abscess
Study NCT01344174 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 5 days dexamethasone therapy
Description: dexamethasone 10mg, intravenously, po daily for the first 5 days
Study NCT03185442 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed Radiofrequency
Description: Pulsed Radiofrequency is performed if the sensory threshold is below 0.5 volts, the PRF consists of 380 pulses
Study NCT02436733 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pleurectomy/decortication
Description: Lung sparing procedures consist of the resection of the pleura without removing the lung
Study NCT02436733 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pleurectomy/decortication
Description: Lung sparing procedures consist of the resection of the pleura without removing the lung
Study NCT01711528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given SC
Study NCT02436733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed/Cisplatin
Description: On day 1 of each cycle, pemetrexed 500 mg/m2 should be administered as IV infusion followed by cisplatin 75 mg/m2 as IV.
Study NCT02436733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed/Cisplatin
Description: On day 1 of each cycle, pemetrexed 500 mg/m2 should be administered as IV infusion followed by cisplatin 75 mg/m2 as IV.
Study NCT01499719 — intervention group
Intervention type: BEHAVIORAL
Intervention: Checklist introduction / Pause
Description: Operating room staff will be introduced to a new checklist specifically designed to address concerns around protocols for endoscopic sinus surgery to raise awareness and attention to 11 specific areas of interest.
Study NCT01010854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VPA FEC100
Description: oral VPA (60 mg/kg bid) q 12h X 6 with IV 5-Fluorouracil (500 mg/m2) Epirubicin (100 mg/m2) and Cyclophosphamide (500 mg/m2)
Study NCT01441791 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung protective strategy ventilation
Description: Patients are randomized and intra-operatively ventilated with a lung protective strategy (PEEP at 12 cmH2O with recruitment maneuvers)
Study NCT01688635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2963016
Description: Administered subcutaneously
Study NCT01688635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: US Approved Lantus
Description: Administered subcutaneously
Study NCT00939939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin
Description: sitagliptin 100 mg/d for 10 weeks
Study NCT00939939 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glimepiride
Description: glimepiride 1 mg/d for 10 weeks
Study NCT03103880 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BreatheSmart
Description: BreatheSmart is a comprehensive asthma monitoring system that combines a medical device and mobile application that are designed for use with Apple and Android mobile devices. The medical device connects to the mobile application using Bluetooth to facilitate the collection of controlled medication adherence, rescue medication usage, and asthma control.
Study NCT00861588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isoflavones (Soylife 25)
Description: 40mg of soy isoflavones capsule (once daily)
Study NCT00861588 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: starch placebo
Study NCT02178072 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 5-Azacitadine
Study NCT02131545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine 25 mg gel applied topically
Description: Quetiapine 25 mg gel applied topically; 9 serum quetiapine levels drawn over the course of 8 hours
Study NCT02131545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine 25 mg tablet by mouth
Description: Quetiapine 25 mg tablet administered by mouth; 9 serum quetiapine levels drawn over the course of 8 hours
Study NCT02131545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine 25 mg rectal suppository
Description: Quetiapine 25 mg suppository administered rectally; 9 serum quetiapine levels drawn over the course of 8 hours
Study NCT02131545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine 25 mg gel applied topically
Description: Quetiapine 75 mg gel applied topically every 4 hours for 24 hours; 6 serum quetiapine levels drawn over the course of 24 hours
Study NCT00799760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oseltamivir + zanamivir
Description: oral oseltamivir 75mg twice daily + zanamivir 10 mg inhaled by mouth twice daily during 5 days
Study NCT00799760 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oseltamivir + zanamivir's placebo
Description: oral oseltamivir 75mg twice daily+ placebo inhaled by mouth twice daily during 5 day
Study NCT00799760 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oseltamivir's placebo + zanamivir
Description: oral placebo twice daily + zanamivir 10 mg inhaled by mouth twice daily during 5 day
Study NCT04570514 — intervention group
Intervention type: PROCEDURE
Intervention: PCI
Description: percutaneous coronary intervention (PCI)
Study NCT03967509 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comet
Study NCT00900445 — intervention group
Intervention type: DRUG
Intervention: Daunorubicin Hydrochloride
Description: Given IV
Study NCT00900445 — intervention group
Intervention type: OTHER
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT00900445 — intervention group
Intervention type: DRUG
Intervention: Prednisolone
Description: Given orally
Study NCT00900445 — intervention group
Intervention type: DRUG
Intervention: Prednisone
Description: Given orally
Study NCT00900445 — intervention group
Intervention type: DRUG
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT04766736 — intervention group
Intervention type: PROCEDURE
Intervention: Quantification of netrin-1 signals by antibody-based approaches
Description: Samples have been obtained upon curative surgery without any other therapy administered and subsequently characterized by pathologists after FFPE inclusion.
Study NCT03914950 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PET/CT results with TOF/without TOF
Description: Diagnostic CT of the abdomen or upper abdomen with parenteral contrast medium (Visipaque=Iodixanol) if creatinine, GFR, and TSH levels are within the normal range and oral (water) contrast medium within TOF-18F-FDG PET/CT. In the case of elevated creatine or decreased GFR or TSH levels a diagnostic CT of the abdomen or upper abdomen without contrast medium is performed.~Biopsy or FNA or operation of the pancreas.
Study NCT01289665 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lubricating gel used during speculum insertion.
Description: Examiner will use 0.5 mL of sterile lubricating gel to lubricate standard-sized plastic speculum during clinically indicated vaginal speculum examination. Patients will mark visual analog scale immediately following insertion.
Study NCT01289665 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Water used during speculum examination.
Description: Patients will under vaginal speculum examination using 3 mL of water as a lubricant and will mark a visual analog scale immediately after speculum insertion.
Study NCT01046266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5083945
Description: 700mg iv weekly
Study NCT01046266 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cetuximab
Description: 400mg/m2 iv 1st dose, 250mg/m2 iv subsequent weekly doses
Study NCT00773734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast 10mg
Study NCT00773734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast 20mg
Study NCT00773734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg
Study NCT00773734 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00773734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast 30mg
Study NCT02717858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Injected s.c./subcutaneously (under the skin) Dose escalation period starting with liraglutide 0.6 mg per day and escalated with weekly increments of 0.6 mg until the target dose 3.0 mg is reached.
Study NCT02717858 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Injected s.c./subcutaneously (under the skin) once daily.
Study NCT03547336 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theranova 400 Dialyzer
Description: Dialysis performed in HD mode. Treatment duration for each individual subject will vary based on clinical requirements determined by the Investigator, based on the subject's need, residual renal function, access function, tolerance to HD/HDF and other relevant factors. The participating subjects' HD/HDF prescriptions should be kept stable throughout the study.
Study NCT03547336 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FX800 Dialyzer
Description: Dialysis performed in HDF mode. Treatment duration for each individual subject will vary based on clinical requirements determined by the Investigator, based on the subject's need, residual renal function, access function, tolerance to HD/HDF and other relevant factors. The participating subjects' HD/HDF prescriptions should be kept stable throughout the study.
Study NCT02439671 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: McGill Transition Support Program
Description: The McGill Transition Support Program is manual-based, including 15 modules of curriculum, five in each of the following domains of skills:~* Social communication (e.g. listening, perspective taking)~* Self-determination (e.g. problem-solving, self-advocacy)~* Working with others (e.g. knowing your context, teamwork)~Nine out of the 15 modules are selected for each group according to the common needs endorsed by participants on a needs assessment questionnaire. Each group consists of 4 adults and two facilitators who were graduate students in Speech Language Pathology or Educational Psychology.~The intervention follows a Self-Determination Learning Model of Instruction (SDLMI) that considers the individual's strengths and needs in the development of personal goals and plans for one's future. A workbook is used to accompany each module with the aim of having the participants practice and generalize the main content messages.
Study NCT04334486 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Super Smash Brothers Melee (Gamecube)
Description: 10 minutes of participation in Super Smash Brothers Melee prior to Eyesi Surgical Simulator evaluation of skills.
Study NCT00688376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil hydrochloride
Description: During the 12-week Double-Blind Phase, subjects will receive oral donepezil hydrochloride tablets starting at a dose of 3 mg once daily. Doses will be increased incrementally at successive 3-week intervals on the basis of weight and tolerability. The final daily dose will be 3, 5, or 10 mg depending on body weight.~During the Blinded Extension Phase, all subjects will receive active treatment (donepezil).
Study NCT00688376 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: During the 12-week Double-Blind Phase, subjects will receive matching placebo tablets (3, 5, of 10 mg) once daily.~During the 12-week Blinded Extension Phase, all subjects will receive active treatment (donepezil).
Study NCT01150617 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine plus insulin analogues
Description: * Intensified insulin therapy: three administrations of regular insulin or short acting insulin analogues before meals combined with long-acting insulin analogue glargine in the evening. The treatment goal will be a fasting blood glucose level of 5.5 mmol/L (99 mg/dl) and a HbA1c\<6.5% at the end of the follow-up.~* Standard care: treatment will be once-daily long-acting insulin and oral antidiabetic agents to achieve HbA1c levels of \< 7.0% at the end of the follow-up.
Study NCT04160429 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of sweat, saliva, and blood samples
Study NCT04160429 — intervention group
Intervention type: OTHER
Intervention: Medical Chart Review
Description: Review of medical chart
Study NCT01233648 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: rate control via CRT-D and AVN ablation
Description: rate control
Study NCT01233648 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: rhythm control via pharmacologic, electrical or ablative therapies
Description: rhythm control
Study NCT01836406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine and remote ischemic preconditioning
Description: Ketorolac tromethamine/ single / 1mg/kg/ intravenous administration 30 min before renal artery clamping, remote ischemic preconditioning / 200 mmHg / 5 min inflation and 10 min deflation / 3 cycles / after anesthetic induction
Study NCT04530240 — intervention group
Intervention type: PROCEDURE
Intervention: Liver Transplantation
Description: Use prospectively collected databases from each participate centre, register MELD score recorded at the time of drop-out, liver transplantation and end of the follow-up.
Study NCT04050150 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Arm training in standing
Description: Arm training will be provided in one hour sessions, 3 time per week for 8 weeks. In each session, you will practice functional tasks with your weaker arm and hand in standing or during walking. Practice will be scaled to match your current level of function and progressed over time as able.
Study NCT01711528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO
Study NCT01711528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinaciclib
Description: Given IV
Study NCT01711528 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT05123014 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: relex smile
Description: In OCT, firstly, the thickness of the adenoviral subepithelial infiltration in the cornea is calculated in microns, and extraction is performed accordingly with Small Incision Lenticule Extraction( SMILE )and fresh lenticule implanted stromal in the same volume.
Study NCT01020461 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accuvein
Description: Accuvein will be used to facilitate venous blood sampling
Study NCT01020461 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accuvein
Description: Accuvein will be used to facilitate peripheral IV catheter placement
Study NCT04317235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.5% Injectable Solution
Description: Is to put 3 ml or 5 ml and show the difference
Study NCT00702832 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation
Description: Daily home training (4-6 specific exercises) 2-3 times per day. Group training led by a physiotherapist twice per week during the first 10 weeks and once per week from 10 weeks to 12 months or to symptoms are cured.
Study NCT00702832 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment
Description: treatment as usual
Study NCT04256187 — intervention group
Intervention type: OTHER
Intervention: Qualitative interview
Description: Qualitative interviews to sample the patient's feelings, experiences and thoughts risen by the treatments in the program.
Study NCT01884363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Once ounce per day of walnuts
Study NCT01550601 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: bariatric surgery
Description: The longitudinal gastrectomy (sleeve gastrectomy) is a technique of bariatric surgery recently validated (HAS on 2008).It consists of the realization of a partial gastrectomy of 2/3 (Fundus, gastric Body +/- antrum). However, lot of technical disagreements are brought back by expert teams. The most important disagreement concerns the conservation or the exeresis of the gastric antrum. In fact, the conservation of gastric antrum could facilitate the gastric emptying and to decrease the RGO (main complication) and act on the regulations of hormones modulators of the insulino-secretion.
Study NCT01550601 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bariatric surgery
Description: The longitudinal gastrectomy (sleeve gastrectomy) is a technique of bariatric surgery recently validated (HAS on 2008).It consists of the realization of a partial gastrectomy of 2/3 (Fundus, gastric Body +/- antrum). However, lot of technical disagreements are brought back by expert teams. The most important disagreement concerns the conservation or the exeresis of the gastric antrum. In fact, the conservation of gastric antrum could facilitate the gastric emptying and to decrease the RGO (main complication) and act on the regulations of hormones modulators of the insulino-secretion.
Study NCT04160429 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaire
Study NCT04126707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] HQP1351
Description: Orally, single dose of 30mg
Study NCT02677129 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: home-based exercise intervention
Description: Endurance training (moderate intensity; walking), 3-5 times per week Patients will receive exercise counselling how to realize the planned intervention home-based. Further, they will be asked to fill out an exercise log. The study team will periodically review adherence to the intervention and identify problems.
Study NCT01791816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Phenylephrine dose-response comprises infusion of 0.5, 1, 2, 3, 4 micrograms/kg/min for 10 min at each dose.~If bloods pressure increases by 30% or if heart rate decreases below 40 beats per minute we will stop infusion.
Study NCT01791816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Ng-monomethyl Arginine (L-NMMA)
Description: Systemic L-NMMA is infused as a 500μg/kg/min loading dose for 15 min followed by a 50μg/kg/min maintenance dose for the remainder of the experiment.
Study NCT01244672 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ferguson
Description: This is a modification of the Milligan-Morgan technique, whereby the incisions are totally or partially closed with absorbable running suture. A retractor is used to expose the hemorrhoidal tissue, which is then removed surgically. The remaining tissue is either sutured or is sealed through the coagulation effects of a surgical device.
Study NCT01244672 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: THD
Description: Transanal hemorrhoidal dearterialization will be performed using an endoscopic ultrasonic probe. Approximately 7-8 hemorrhoidal arteries will be ligated at 1, 3, 5, 7, 9, 11 o'clock position as previously described in the literature. The ligation will be performed using a vicryl suture. The ultrasonic probe locates the arterial signal.
Study NCT03067116 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Posturography Evaluation
Description: Posturography testing using the modified Clinical Testing of Sensory Integration in Balance (mCTSIB) protocol: the subjects will be required to stand on a hard or compliant surface in a comfortable posture, with eyes open or closed
Study NCT03067116 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Anthropometrics
Description: measurement of height, minimum stance width (feet together or as close as they can be), circumference of the torso at the breast level, of the abdomen, of the hip, and of each thigh, and supine fundal height
Study NCT03067116 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Vitals
Description: measurement (bilateral and seated/standing if applicable) of temperature, respiration rate, heart rate, blood pressure, pulse oxygenation and heart rate variability
Study NCT03067116 — intervention group
Intervention type: OTHER
Intervention: Health and daily activity questionnaires
Description: one time general health questionnaire as well as session questionnaires asking the subjects if they have fallen since their last testing session and how comfortable they are in doing daily activities